Q: When can I stop dual antiplatelet therapy in patients with drug-eluting stents?

A: Stopping dual antiplatelet therapy (DAPT) (eg, clopidogrel plus aspirin) after 3 months is reasonable in patients with stable ischemic heart disease who have a second-generation drug-eluting stent and a high bleeding risk, with stable ischemic disease defined as at least 1 year free of acute coronary syndromes. However, these patients should continue lifelong aspirin monotherapy. Current guidelines suggest that in stable ischemic disease, the risk-benefit ratio may favor an even shorter duration of DAPT than the 6 months currently recommended.1

**STABLE ISCHEMIC HEART DISEASE VS ACUTE CORONARY SYNDROME**

Percutaneous coronary intervention for stable ischemic heart disease is indicated primarily in patients with angina that persists despite optimal antianginal therapy.

The prognostic implications of DAPT are different in stable ischemic disease than in acute coronary syndromes. The substrate treated by percutaneous intervention in stable ischemic disease is primarily fibrofatty plaque, as opposed to thrombus in acute coronary syndromes.

Percutaneous intervention significantly improves the prognosis in acute coronary syndromes, whereas its impact on overall survival in stable ischemic heart disease is not well documented. Given these differences, our discussion about DAPT in stable ischemic disease cannot be extrapolated to acute coronary syndromes.

**BENEFITS OF DAPT**

DAPT is mandatory early after drug-eluting stent placement, when the stent continuously releases medication, inhibiting tissue growth within the lumen of the stent.

Endothelialization of the stent normally occurs during the first 7 to 30 days after placement. During this period, the nonendothelialized stent poses a risk of thrombosis, a life-threatening, catastrophic condition with a mortality rate between 9% and 45%.1

Aspirin 75 to 100 mg has been shown to be effective as secondary prevention of atherosclerotic disease and is recommended lifelong in this clinical setting. Adding a thienopyridine reduces the risk of myocardial infarction, stent thrombosis, and death from a cardiovascular event and decreases the incidence of plaque rupture in nonstented coronary vessels. Hence, prevention of these complications provides the rationale for DAPT in this clinical setting.

**THERAPY BEYOND 12 MONTHS**

Although guidelines have traditionally recommended 12 months of DAPT, the optimal duration is still debated.
A duration beyond 12 months in patients with a history of myocardial infarction was shown to be reasonable in 2 large trials, while a 2016 review by Bittl et al suggested that therapy beyond 12 months in patients with a newer-generation drug-eluting stent could increase the incidence of major bleeding. A detailed discussion of DAPT longer than 12 months is beyond the scope of this article.

■ EVIDENCE FOR SHORTER DURATION

The results of 5 major trials support shorter duration of DAPT in stable ischemic disease. The OPTIMIZE5 and RESET6 trials found that 3 months of DAPT was not inferior to 12 months in terms of ischemic and safety end points. The ISAR-SAFE,7 EXCELLENT,8 and SECURITY9 trials also reported that 6 months of DAPT was not inferior to 12 months for the primary composite end point of death, stent thrombosis, myocardial infarction, stroke, or major bleeding.

However, these trials may have been underpowered to detect a difference in rates of stent thrombosis with shorter-duration DAPT.

■ CURRENT GUIDELINES

For patients at high bleeding risk, the current guidelines of the American College of Cardiology and American Heart Association, updated in 2016, suggest that it may be reasonable to discontinue DAPT 3 months after drug-eluting stent placement in patients with stable ischemic heart disease, and at 6 months in patients with acute coronary syndrome (class IIb recommendation, level of evidence C).1 These recommendations are based on results of randomized controlled trials showing no difference in the rate of stent thrombosis and composite ischemic events with a shorter duration than with 12 months of therapy.5–10

The evidence for DAPT in stable ischemic disease is based on clopidogrel, with only limited data on ticagrelor. Since 2017, all coronary stents implanted in the United States have been second-generation stents.

### TABLE 1

<table>
<thead>
<tr>
<th>Risk factors for ischemia, stent thrombosis, and bleeding</th>
<th>Ischemiaa</th>
<th>Stent thrombosisa</th>
<th>Bleedingb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced age</td>
<td>Acute coronary syndrome</td>
<td>Acute coronary syndrome</td>
<td>History of bleeding</td>
</tr>
<tr>
<td>Acute coronary syndrome at presentation</td>
<td>Diabetes mellitus</td>
<td>Diabetes mellitus</td>
<td>Female</td>
</tr>
<tr>
<td>Previous myocardial infarction</td>
<td>Left ventricular ejection fraction &lt; 40%</td>
<td>First-generation drug-eluting stent</td>
<td>Advanced age</td>
</tr>
<tr>
<td>Extensive coronary artery disease</td>
<td>Stent undersizing</td>
<td>Stent undersizing</td>
<td>Low body weight</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Stent underdeployment</td>
<td>Stent undersizing</td>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>Small stent diameter</td>
<td>Small stent diameter</td>
<td>Anticoagulation</td>
</tr>
<tr>
<td></td>
<td>Greater stent length</td>
<td>Greater stent length</td>
<td>Chronic nonsteroidal anti-inflammatory drug or steroid therapy</td>
</tr>
<tr>
<td></td>
<td>Bifurcation stents</td>
<td>Bifurcation stents</td>
<td>Anemia</td>
</tr>
<tr>
<td></td>
<td>In-stent restenosis</td>
<td>In-stent restenosis</td>
<td></td>
</tr>
</tbody>
</table>

a These factors favor consideration of a longer duration of dual antiplatelet therapy.
b These factors favor consideration of a shorter duration of dual antiplatelet therapy.

TOOLS TO HELP DECISION-MAKING

The decision to stop DAPT in a patient at high risk of bleeding requires a careful assessment of the risks and benefits. Risk factors for bleeding include advanced age, history of major bleeding, anticoagulation, chronic kidney disease (serum creatinine level ≥ 2 mg/dL), platelet count 100 × 10^9/L or lower, and history of stroke.11

A useful approach is to define the risks of stent thrombosis and bleeding (Table 1).1 The DAPT score determines the risk-benefit ratio for long-term DAPT as follows:

- Age 75 or older: −2 points
- Ages 65 to 74: −1
- Age under 65: 0
- Diabetes mellitus: 1
- Myocardial infarction at presentation: 1
- History of percutaneous coronary intervention or myocardial infarction: 1
- Stent diameter less than 3 mm: 1
- Paclitaxel drug-eluting stent: 1
- Current smoker: 2
- Percutaneous coronary intervention with saphenous vein graft: 2
- Congestive heart failure or left ventricular ejection fraction less than 30%: 2.

A score of 2 or greater favors continuing DAPT, as it indicates higher ischemic risk. A score less than 2 favors discontinuing DAPT, as it indicates higher bleeding risk.1,2

IF BLEEDING RISK IS HIGH

Preventing and controlling bleeding associated with DAPT is important. The gastrointestinal tract is the most common site of bleeding. Aspirin inhibits prostaglandin synthesis, leading to disruption of the protective mucous membrane. Therefore, a proton pump inhibitor should be started along with DAPT in patients at high risk of gastrointestinal bleeding.

If a patient's bleeding risk significantly outweighs the risk of stent thrombosis, or if active hemorrhage makes a patient hemodynamically unstable, antiplatelet therapy must be stopped.1

FACING SURGERY

For patients with a drug-eluting stent who are on DAPT and are to undergo elective noncardiac surgery, 3 considerations must be kept in mind:

- The risk of stent thrombosis if DAPT needs to be interrupted
- The consequences of delaying the surgical procedure
- The risk and consequences of peri- and intraprocedural bleeding if DAPT is continued.

Because clinical evidence for bridging therapy with intravenous antiplatelet or anticoagulant agents is limited, it is difficult to make recommendations about stopping DAPT. However, once bleeding risk is stabilized, DAPT should be restarted as soon as possible.1

CURRENT RESEARCH

Several trials are under way to further evaluate ways to minimize bleeding risk and shorten the duration of DAPT.

A prospective multicenter trial is evaluating 3-month DAPT in patients at high bleeding risk who undergo placement of an everolimus-eluting stent.11 This study is expected to be completed in August 2019.

Another strategy for patients at high bleeding risk is use of a polymer-free drug-coated coronary stent. In a 2015 trial comparing a biolimus A9-coated stent vs a bare-metal stent, patients received DAPT for 1 month after stent placement. The drug-coated stent was found to be superior in terms of the primary safety end point (cardiac death, myocardial infarction, or stent thrombosis).12 This stent is not yet approved by the US Food and Drug Administration at the time of this writing.

Further study is needed to evaluate DAPT durations of less than 3 months and to establish the proper timing for safely discontinuing DAPT in difficult clinical scenarios.

WHEN STOPPING MAY BE REASONABLE

According to current guidelines, in patients at high bleeding risk with a second-generation or newer drug-eluting stent for stable ischemic heart disease, discontinuing DAPT 3 months after stent placement may be reasonable.1 The decision to stop DAPT in these patients requires a careful assessment of the risks and benefits and may be aided by a tool such as the DAPT risk score. However, these
DUAL ANTIPLATELET THERAPY

recommendations cannot be extrapolated to patients with an acute coronary syndrome within the past year, as they are at higher risk.

■ TAKE-HOME MESSAGES

- A cardiologist should be consulted before discontinuing DAPT in patients with a drug-eluting stent, especially if the stent was recently placed.
- The duration of therapy depends on the indication for stent placement (stable ischemic heart disease vs acute coronary syndrome) and on stent location.
- Based on the 2016 American College of Cardiology/American Heart Association guidelines, in patients at high bleeding risk with a second-generation drug-eluting stent, discontinuing DAPT is safe after 3 months in patients with stable ischemic heart disease, and after 6 months in patients with an acute coronary syndrome.
- When prescribing DAPT, available evidence favors clopidogrel in patients with stable ischemic heart disease who have a second-generation drug-eluting stent and are at high bleeding risk.
- In these patients, the risk-benefit ratio based on the DAPT score may be useful when considering stopping clopidogrel.

■ REFERENCES


ADDRESS: Juan Simon Rico-Mesa, MD, Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; juansimonrico@hotmail.com

Downloaded from www.ccjm.org on August 3, 2022. For personal use only. All other uses require permission.